Health & Biotech
ASX Health Stocks: PYC’s visionary drug shows promise; Spontan ED spray available under TGA program
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
Coles boosts its exposure of The Calmer Co’s products by 40pc
ASX Quarterly Health Wrap – Who kicked off a pivotal trial last quarter?
The Calmer Co. achieves record sales in Q4 and plans US expansion
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
NorthStar sees good impact in Control Bionics, invests $525k
Lumos Diagnostics’ strong Q4 paves way for exciting phase of growth
Neurotech’s Rett Syndrome trial shows improvement in extension stage
Diagnosing Depression in Your Sleep: TrivarX delivers positive Phase 2 study results
MoneyTalks: Horizon 3 Healthcare is bullish on these two ASX firms
BlinkLab partners with Mental Care Group to advance ADHD diagnostics in Europe
Race Oncology’s lead drug AML study successfully concludes
ASX Quarterly Health Wrap: Who is making progress for FDA approval?
ASX Health Stocks: HITIQ secures US patent; BlinkLab joins forces in Europe to transform ADHD diagnosis
Aussie made: ASX firms boosting local health & medical manufacturing
AdAlta boosts balance sheet, makes key advances in Q4 FY24
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
